Relevant bibliographies by topics / Minimal Residual Disease Detection

Academic literature on the topic 'Minimal Residual Disease Detection'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Minimal Residual Disease Detection.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Minimal Residual Disease Detection"

1

MORITA, KIMIO. "Detection of Minimal Residual Disease." KITAKANTO Medical Journal 48, no. 3 (1998): 229–31. http://dx.doi.org/10.2974/kmj.48.229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hangenbeek, A. "Detection of minimal residual disease." Current Diagnostic Pathology 1, no. 4 (December 1994): 240. http://dx.doi.org/10.1016/0968-6053(94)90021-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Carlo-Stella, Carmelo, Lina Mangoni, Gian Pietro Dotti, and Vittorio Rizzoli. "Techniques for Detection of Minimal Residual Disease." Leukemia & Lymphoma 18, sup1 (January 1995): 75–80. http://dx.doi.org/10.3109/10428199509075308.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Katz, F. E. "Detection of minimal residual disease in leukaemia." Archives of Disease in Childhood 67, no. 6 (June 1, 1992): 671–73. http://dx.doi.org/10.1136/adc.67.6.671.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Weitz, J�rgen, and Christian Herfarth. "Surgical strategies and minimal residual disease detection." Seminars in Surgical Oncology 20, no. 4 (2001): 329–33. http://dx.doi.org/10.1002/ssu.1051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Eldessouki, Ihab A., Ola Khorshid, Eman Kandeel, and Nasr Lahloubi. "Minimal Residual Disease In Adult AML." Blood 122, no. 21 (November 15, 2013): 4969. http://dx.doi.org/10.1182/blood.v122.21.4969.4969.

Full text
Abstract:
Abstract Background The achievement of complete hematologic remission (CR) is used as predictor for treatment response in patients with myeloid leukemia (AML).However <5% blasts in the bone marrow does not reflect the presence of tumor burden precisely. Minimal residual disease (MRD) in the first complete remission (CR1) may play a critical rule in assessment of treatment response and prediction of subsequent relapse. Patients and Methods Leukemia associated immunophenotyping (LAIP) for 73 patients with denovo AML monitored at diagnosis , day 14 and day28 post-induction by multiparametric flow cytometry (MFC). Results CR achieved in 60(82%) patients and 13(18%) patients did not. Among the 60(80%) patients who achieved CR 9 (15%) were MRD negative and 51(85%) were MRD positive at day14. Significant association between MRD detection and disease free survival (DFS) using 0.01% cut off value (P=.015). Day 28 post induction show highly significant association between MRD and DFS using 0.01% cut off value (P=0.001) as 38(63%) patients were MRD negative and (27%) were positive. Significant association between MRD detection and overall survival (50 month) at day 14 and day 28 (P=0.02, P=0.001) respectively using cut off value 0.01%. MRD was positive in 63(86%) at day 14 and (37%) at day 28. Conclusion MRD detection at day28 and d14 at the end of induction in patients in CR may have a prognostic significance on clinical outcome and may thus be a useful marker for risk stratification. Disclosures: No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
7

Chudacek, Josef, Tomas Bohanes, Jiri Klein, Andrea Benedikova, Josef Srovnal, Marek Szkorupa, Pavel Skalicky, Jozef Skarda, Marian Hajduch, and Cestmir Neoral. "Detection of minimal residual disease in lung cancer." Biomedical Papers 158, no. 2 (June 23, 2014): 189–93. http://dx.doi.org/10.5507/bp.2013.019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Andreani, Giacomo, and Daniela Cilloni. "Strategies for minimal residual disease detection: current perspectives." Blood and Lymphatic Cancer: Targets and Therapy Volume 9 (February 2019): 1–8. http://dx.doi.org/10.2147/blctt.s172693.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sausville, Justin E., Rita G. Salloum, Lynn Sorbara, Douglas W. Kingma, Mark Raffeld, Robert J. Kreitman, Paula D. Imus, David Venzon, and Maryalice Stetler-Stevenson. "Minimal Residual Disease Detection in Hairy Cell Leukemia." American Journal of Clinical Pathology 119, no. 2 (February 2003): 213–17. http://dx.doi.org/10.1309/g6299513nglcub1k.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Paietta, Elisabeth. "Leukemia and Lymphoma: Detection of Minimal Residual Disease." Medical Oncology 20, no. 3 (2003): 307–10. http://dx.doi.org/10.1385/mo:20:3:307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Minimal Residual Disease Detection"

1

Uzunel, Mehmet. "The methodology and significance of minimal residual disease detection after allogeneic stem cell transplantation /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-619-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Steward, Colin Graham. "Technical aspects of minimal residual disease detection in childhood B-lineage acute lymphoblastic leukaemia." Thesis, University of Bristol, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Langlands, Kenneth. "Application of molecular analysis to the detection and study of minimal residual disease in haematological neoplasms." Thesis, University of Edinburgh, 1994. http://hdl.handle.net/1842/19913.

Full text
Abstract:
The aims of this study are i) to screen tumour from patients with leukaemia and lymphoma and determine the incidence of tumour markers, t(14;18) translocation, T-cell receptor δ (TcRδ) chain and immunoglobulin heavy chain (IgH) gene rearrangements ii) to develop sensitive PCR based techniques using these tumour markers and iii) to analyse serial remission samples and peripheral blood stem cells (PBSC) for residual tumour. Southern bolt analysis showed that 55% of patients with pre-B acute lymphoblastic leukaemia (ALL) had TcR Vδ2-Dδ3 rearrangements and that 85% of patients with B-lineage disease had IgH rearrangements. PCR analysis showed a TcRδ marker in 53% of pre B ALL and a CDRIII marker in 77% of B-lineage disorders therefore these patients were available for further study of minimal disease. Direct sequence analysis of PCR products from TcR Vδ2-Dδ3 and the third complementarity-determining region (CDRIII) of IgH demonstrated sufficient junctional diversity to permit unique clone specific probes of 20 nucleotides to be designed. Junctional diversity was generated by random N- nucleotide insertion, gene segment deletion and addition of other D segments.
APA, Harvard, Vancouver, ISO, and other styles
4

Papadaki, Christina [Verfasser], and Karsten [Akademischer Betreuer] Spiekermann. "Detection of minimal residual disease in Acute Myeloid Leukemia with t(8;21) translocation / Christina Papadaki ; Betreuer: Karsten Spiekermann." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2017. http://d-nb.info/1138195545/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dang, Raymond K. B. "Molecular detection of minimal residual disease in breast cancer and leukaemias using p53 tumour suppressor gene mutations as markers." Thesis, University of Edinburgh, 2000. http://hdl.handle.net/1842/22132.

Full text
Abstract:
The use of peripheral blood progenitor cell (PBPC) transplantation is an important advance in the treatment of breast cancer and acute leukaemias, and these conditions are among the commonest indications for this procedure. Inevitably, there is concern that malignant cells may contaminate progenitor cell harvests and be re-infused during transplantation and cause disease relapse. Various methods are available for the detection of such minimal residual disease (MRD), and the key aim of this project was to evaluate the feasibility of using a tumour-specific marker, namely mutations within the p53 gene, for this purpose. This provided a useful model to assess the feasibility of using subtle genetic changes to detect MRD within PBPC harvests from patients with malignant diseases. The first step involved the use of denaturing gradient gel electrophoresis (DGGE) to screen original tumour tissues for mutations to be used as disease markers, in 5 individually PCR-amplified DNA fragments (A to E) covering exons 5 to 8 of p53. The technique was first optimised using cell lines known to contain p53 mutations in each fragment. Optimisation was performed with respect to electrophoresis temperature, time, voltage and polyacrylamide cross-linker. The sensitivity of DGGE in detecting a mutation in a mixed cell population was determined by diluting tumour cells in wild type (WT) cells. Although the presence of a mutation could be demonstrated when tumour cells occurred as 5% of total, a representation of at least 40% was required for the mutant homoduplex to be isolated for sequencing. Clinical samples studied were from 51 breast cancer patients, 38 of whom had metastatic disease or at high risk of metastasis, and 13 had high risk stage II/III disease randomised in a clinical study investigating PBPC transplantation and adjuvant therapy, and from 29 patients with acute leukaemias. A positive result was obtained in 14 of 51 primary breast cancer patients (1 was positive in 2 different fragments) and 3 of 29 patients with acute leukaemias.
APA, Harvard, Vancouver, ISO, and other styles
6

Chan, Wai. "Clonal rearrangement of T-cell receptor delta gene in hematological malignancies and applications in detection of minimal residual disease /." Hong Kong : University of Hong Kong, 1995. http://sunzi.lib.hku.hk/hkuto/record.jsp?B1705512X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Woerner, Sandra Maria [Verfasser], Monika [Akademischer Betreuer] Engelhardt, and Robert [Akademischer Betreuer] Zeiser. "Establishment of a 6-, 8- and 10-color multiparameter flow cytometry assay for the detection of minimal residual disease in multiple myeloma patients: challenging diversity in a straightforward approach." Freiburg : Universität, 2019. http://d-nb.info/1233196715/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Thörn, Ingrid. "Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia." Doctoral thesis, Uppsala universitet, Institutionen för genetik och patologi, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-101028.

Full text
Abstract:
Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy of bone marrow (BM) smears, but due to more effective therapies more sensitive methods are needed. Today, detection of minimal residual disease (MRD) using immunological and molecular techniques can be 100 times more sensitive than morphology. The main aim of this thesis was to compare and evaluate three currently available MRD methods in childhood acute lymphoblastic leukemia (ALL): (i) real-time quantitative PCR (RQ-PCR) of rearranged antigen receptor genes, (ii) multicolor flow cytometry (FCM) of leukemia-associated immunophenotypes and (iii) real-time quantitative PCR of fusion gene transcripts (RT-PCR). In paper I, we assessed the applicability of RQ-PCR in a population-based cohort of childhood ALL diagnosed in Sweden between 2002-2006. Clonal IG/TCR rearrangements were identified in the 96% of the 279 ALL cases. Using RQ-PCR, the quantitative range of 10-3 was reached in 93% of B-cell precursor (BCP) ALL and 86% of T-cell ALL (T-ALL) by at least one target gene. In paper II, we compared MRD detection using both RQ-PCR and FCM in the context of NOPHO ALL-2000 protocol. By applying the stratification threshold of ≥0.1% MRD late during induction therapy (day 29), we could demonstrate that both methods can predict the risk of BM relapse but not extramedullary relapse. However, the threshold of ≥0.2% MRD appears to be more optimal using RQ-PCR in BCP ALL, whilst in T-ALL, the results indicate that RQ-PCR is preferable for MRD assessment. The stability of RNA in vitro is a critical factor when using sensitive molecular techniques such as MRD detection. In paper III, we evaluated the influence on MRD detection when blood is collected in tubes with RNA stabilization reagents (PAX gene Vacutatiner®) compared to collection in EDTA-tubes (non-stabilized). We analyzed 68 matched samples from chronic myeloid leukemia patients and the results indicated that non-stabilized blood processed within 30 hours is preferable for MRD detection. In paper IV, follow-up samples from eight children with Philadelphia positive (Ph+) ALL were evaluated with the three available MRD methods. MRD measured by the fusion gene transcripts (BCR-ABL1) appeared to be the most sensitive method, however, precise quantification can be difficult and the other methods are thus complementary. In conclusion, all three applied MRD methods are useful and correlate to each other, although not necessary exchangeable in individual patients. We also conclude that MRD assessment by RQ-PCR, based on rearranged IG/TCR genes and multicolor FCM are predictive for identification of high risk childhood ALL patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Thörn, Ingrid. "Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-101028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Farahat, Nahla Mohamed Gamal. "Minimal residual disease in acute leukaemia by quantitative flow cytometry." Thesis, Institute of Cancer Research (University Of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.244275.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Minimal Residual Disease Detection"

1

F, Zipf Theodore, and Johnston Dennis A, eds. Leukemia and lymphoma: Detection of minimal residual disease. Totowa, N.J: Humana Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Druley, Todd E., ed. Minimal Residual Disease Testing. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-94827-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Reinhold, Uwe, and Wolfgang Tilgen, eds. Minimal Residual Disease in Melanoma. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hagenbeek, Anton, and Bob Löwenberg, eds. Minimal Residual Disease in Acute Leukemia 1986. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4273-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Aguirre-Ghiso, Julio A., ed. Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-97746-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ignatiadis, Michail, Christos Sotiriou, and Klaus Pantel, eds. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-28160-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zipf, Theodore F., and Dennis A. Johnston. Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

F, Zipf Theodore, and Johnston Dennis A, eds. Leukemia and lymphoma: Detection of minimal residual disease. Totowa, N.J: Humana Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zipf, Theodore F., and Dennis A. Johnston. Leukemia and Lymphoma: Detection of Minimal Residual Disease. Humana Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Minimal Residual Disease Detection"

1

Zhou, Yi. "Detection of Minimal Residual Disease." In Practical Lymph Node and Bone Marrow Pathology, 701–11. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-32189-5_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gribben, John, and Lee Nadler. "Detection of Minimal Residual Disease." In Cancer Treatment and Research, 249–70. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-2013-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wilson, Elisabeth R., and R. Spencer Tong. "ML-DS: A Unique Condition for Measurable Residual Disease Detection." In Minimal Residual Disease Testing, 139–57. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94827-0_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Max, N., K. Wolf, B. Spike, E. Thiel, and U. Keilholz. "Nested Quantitative Real Time PCR for Detection of Occult Tumor Cells." In Minimal Residual Disease in Melanoma, 25–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jung, R., K. Soondrum, W. Krüger, and M. Neumaier. "Detection of Micrometastasis Through Tissue-Specific Gene Expression: Its Promise and Problems." In Minimal Residual Disease in Melanoma, 32–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fodstad, Ø., R. Faye, H. K. Høifødt, E. Skovlund, and S. Aamdal. "Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients." In Minimal Residual Disease in Melanoma, 40–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Blaheta, H. J., B. Schittek, H. Breuninger, and C. Garbe. "Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma." In Minimal Residual Disease in Melanoma, 137–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Crowgey, Erin L., and Nitin Mahajan. "Advancements in Next-Generation Sequencing for Detecting Minimal Residual Disease." In Minimal Residual Disease Testing, 159–92. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94827-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

von Knebel Doeberitz, M., J. Weitz, M. Koch, J. Lacroix, A. Schrödel, and C. Herfarth. "Molecular Tools in the Detection of Micrometastatic Cancer Cells — Technical Aspects and Clinical Relevance." In Minimal Residual Disease in Melanoma, 181–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schittek, B., H. J. Blaheta, U. Ellwanger, and C. Garbe. "Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients." In Minimal Residual Disease in Melanoma, 93–104. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Minimal Residual Disease Detection"

1

Comino-Mendez, Iñaki, Ros Cutts, Isaac García-Murillas, Neha Chopra, Maria Afentakis, Abigail Evans, Duncan Wheatley, et al. "Abstract 3608: Molecular fingerprint sequencing for minimal residual disease detection in breast cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3608.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Killinger, K., E. Schneider, O. Schmidt, Z. Czyz, N. Patwary, G. Haunschild, B. Rack, G. Schlimok, and CA Klein. "Minimal residual disease in breast cancer: detection and genomic characterization of disseminated cancer cells." In 40. Jahrestagung der Deutschen Gesellschaft für Senologie e.V. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710708.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Postoperative Mesenchymal Circulating Tumor Cell Detection Monitoring of Minimal Residual Disease in Colorectal Cancer." In 2022 International Conference on Biotechnology, Life Science and Medical Engineering. Clausius Scientific Press, 2022. http://dx.doi.org/10.23977/blsme.2022084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Parsons, Heather A., Justin Rhoades, Sarah C. Reed, Greg Gydush, Priyanka Ram, Pedro Exman, Kan Xiong, et al. "Abstract P5-01-03: Ultrasensitive detection of minimal residual disease in patients treated for breast cancer." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p5-01-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jenderek, C., J. Jückstock, C. Schindlbeck, B. Rack, R. Fuchs, S. Noeding, P. Krabisch, et al. "Minimal residual disease detection in peripheral blood of primary breast cancer patients – translational research in the SUCCESS-study." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-5019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Crowgey, Erin L., Nitin Mahajan, Wing H. Wong, Edward A. Kolb, and Todd Druley. "Abstract 4878: Sensitive and specific DNA and RNA sequencing techniques for detecting minimal residual disease." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4878.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wunderlich, Mark, Nicole Manning, Eric O'Brien, Christina Sexton, Luke Byerly, John P. Perentesis, Benjamin Mizukawa, and James C. Mulloy. "Abstract 5412: Xenograft based detection of rare leukemic clones in minimal residual disease negative diagnostic specimens from pediatric patients." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5412.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Abbosh, Chris, Alexander Frankell, Aaron Garnett, Thomas Harrison, Morgan Weichert, Abel Licon, Selvaraju Veeriah, et al. "Abstract CT023: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-ct023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Druy, Alexander E., Egor V. Shorikov, Grigory A. Tsaur, Alexander M. Popov, Leonid I. Saveliev, and Larisa G. Fechina. "Abstract 1626: Evaluation of the expression of neuroblastoma-associated genes for bone marrow (BM) involvement and minimal residual disease (MRD) detection." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Yu-Hsiang, Bradley A. Hancock, Jeffrey P. Solzak, Bryan P. Schneider, Kathy D. Miller, and Milan Radovich. "Abstract 711: Co-detection of circulating tumor DNA and RNA for enhanced detection of minimal residual disease in patients with chemorefractory triple-negative breast cancer." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-711.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Minimal Residual Disease Detection' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography